Histidine

Histidine

SCHEMBL285488

CSCC[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.44
CPB2 Q96IY4 7/20 0.37
CPB1 P15086 3/20 0.37
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
THRB P10828 1/20 0.35
CYP3A4 P08684 1/20 0.35
SLC7A5 Q01650 1/20 0.35
ARG1 P05089 1/20 0.34
MMP2 P08253 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL23363055 1.00 GSR (0.44) GSRCPB2CPB1ITGB3ITGA2B
Histidine SCHEMBL285636 0.94 GSR (0.39) GSRCPB2CPB1ITGB3ITGA2B
Histidine SCHEMBL285814 0.92 GSR (0.38) GSRCPB2CPB1ITGB3ITGA2B
Histidine SCHEMBL342892 0.92 CYP3A4 (0.40) CYP3A4SLC7A5ARG1CYP1A2
Histidine SCHEMBL27681989 0.92 CYP3A4 (0.40) CYP3A4SLC7A5ARG1CYP1A2
Histidine SCHEMBL342891 0.92 CYP3A4 (0.40) CYP3A4SLC7A5ARG1CYP1A2
Histidine SCHEMBL28650960 0.91 CYP3A4 (0.40) CYP3A4SLC7A5ARG1CYP1A2
Histidine SCHEMBL305855 0.91 GSR (0.54) GSRCPB2CPB1ITGB3ITGA2B
Histidine SCHEMBL4297918 0.91 GSR (0.54) GSRCPB2CPB1ITGB3ITGA2B
Histidine SCHEMBL305856 0.91 GSR (0.54) GSRCPB2CPB1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3103446-A2 PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA Zakharov, Ivan Dmitrievich (RU) 2016-12-14 EP claimed
US-20120135931-A1 METHOD OF MODIFYING SERINE PROTEASE INHIBITORS NATURAL ENVIRONMENT RESEARCH COUNCIL (GB) 2012-05-31 US claimed
EP-2427487-A2 METHOD OF MODIFYING SERINE PROTEASE INHIBITORS Natural Environment Research Council (GB) 2012-03-14 EP claimed
WO-2010128285-A2 METHOD OF MODIFYING SERINE PROTEASE INHIBITORS NATURAL ENVIRONMENT RESEARCH COUNCIL (GB) 2010-11-11 WO claimed
EP-3103446-B1 PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA ZAKHAROV IVAN DMITRIEVICH (RU) 2024-02-14 EP disclosed
EP-3131573-A1 COMPOSITIONS COMPRISING VARIEGIN University of Leeds (GB) 2017-02-22 EP disclosed
US-20170035863-A1 Compositions Comprising Variegin UNIVERSITY OF LEEDS (GB) 2017-02-09 US disclosed
EP-3103446-A2 PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA Zakharov, Ivan Dmitrievich (RU) 2016-12-14 EP disclosed
WO-2015159084-A1 COMPOSITIONS COMPRISING VARIEGIN UNIVERSITY OF LEEDS (GB) 2015-10-22 WO disclosed
US-20120135931-A1 METHOD OF MODIFYING SERINE PROTEASE INHIBITORS NATURAL ENVIRONMENT RESEARCH COUNCIL (GB) 2012-05-31 US disclosed
EP-2427487-A2 METHOD OF MODIFYING SERINE PROTEASE INHIBITORS Natural Environment Research Council (GB) 2012-03-14 EP disclosed
WO-2010128285-A2 METHOD OF MODIFYING SERINE PROTEASE INHIBITORS NATURAL ENVIRONMENT RESEARCH COUNCIL (GB) 2010-11-11 WO disclosed